SCHEMBL2016701

SCHEMBL2016701

O=Cc1ccc2ccc(Br)cc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.52
CCR1 P32246 1/20 0.48
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ERN1 O75460 2/20 0.40
CYP2A6 P11509 4/20 0.38
TERT O14746 1/20 0.37
PABPC1 P11940 1/20 0.36
TYMS P04818 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1002564 0.86 BACE1 (0.53) BACE1CCR1ALDH1A1MEN1MAPT
SCHEMBL14251381 0.80 BACE1 (0.52) BACE1CYP1A2CYP2C19HTTALDH1A1
SCHEMBL15443471 0.78 BACE1 (0.50) BACE1CYP1A2CYP2C19HTTALDH1A1
SCHEMBL10760847 0.78 CYSLTR2 (0.50) ALDH1A1MEN1MAPTKMT2AL3MBTL1
SCHEMBL10760844 0.78 CYSLTR2 (0.50) ALDH1A1MEN1MAPTKMT2AL3MBTL1
SCHEMBL28621619 0.78 CCR1 (0.50) CCR1HTTALDH1A1MEN1MAPT
SCHEMBL2169969 0.76 CCR1 (0.48) BACE1CCR1CYP1A2ALDH1A1MAPT
SCHEMBL3530571 0.76 CYP1A2 (0.55) CCR1CYP1A2ALDH1A1KMT2ACYP2A6
SCHEMBL18572379 0.76 CCR1 (0.48) CCR1CYP1A2ALDH1A1MEN1MAPT
SCHEMBL3748357 0.76 CCR1 (0.48) CCR1ALDH1A1MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-02-02 US disclosed
US-10472392-B2 Macrocyclic inhibitors of flaviviridae viruses GILEAD SCIENCES, INC. (US) 2019-11-12 US disclosed
EP-3392253-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES Gilead Sciences, Inc. (US) 2018-10-24 EP disclosed
EP-2861601-B1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES INC (US) 2018-02-07 EP disclosed
EP-2861601-B1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES INC (US) 2018-02-07 EP disclosed
US-9802918-B2 Pyridineamine compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2017-10-31 US disclosed
US-9802918-B2 Pyridineamine compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2017-10-31 US disclosed
US-9802918-B2 Pyridineamine compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2017-10-31 US disclosed
US-20170190734-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES Selcia Ltd. (GB) 2017-07-06 US disclosed
US-20170190734-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES Selcia Ltd. (GB) 2017-07-06 US disclosed
EP-2582672-A1 X-RAY AND GAMMA-PHOTON ACTIVABLE ORGANIC COMPOUNDS, THEIR PREPARATION AND THEIR USES Centre National De La Recherche Scientifique (FR) 2013-04-24 EP disclosed
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2013-03-14 US disclosed
EP-2397466-B1 X-ray and gamma-photon activatable organic compounds, their preparation and their uses CENTRE NAT RECH SCIENT (FR) 2012-11-28 EP disclosed
EP-2523937-A1 MULTIPHOTON ACTIVABLE QUINOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES Centre National De La Recherche Scientifique (FR) 2012-11-21 EP disclosed
WO-2012154274-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-11-15 WO disclosed
EP-2515903-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF Peter MacCallum Cancer Institute (AU) 2012-10-31 EP disclosed
WO-2011158189-A1 X-RAY AND GAMMA-PHOTON ACTIVABLE ORGANIC COMPOUNDS, THEIR PREPARATION AND THEIR USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-12-22 WO disclosed
EP-2397466-A1 X-ray and gamma-photon activable organic compounds, their preparation and their uses Centre National De La Recherche Scientifique CNRS (FR) 2011-12-21 EP disclosed
WO-2011086469-A1 MULTIPHOTON ACTIVABLE QUINOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-07-21 WO disclosed
WO-2011075784-A1 COMPOUNDS, PREPARATIONS AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472392-B2 Macrocyclic inhibitors of flaviviridae viruses HAVCR2, ZC3HAV1, HCCS BACE1 2938/4885CCR1 370/4885CYP1A2 107/4885
US-20170190734-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, ZC3HAV1, HCCS BACE1 2938/4885CCR1 370/4885CYP1A2 107/4885
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF ROCK1, ROCK2, RHOA BACE1 2989/4885CCR1 3465/4885CYP1A2 2243/4885
US-20130065897-A1 COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, SERPINB1 BACE1 357/4885CCR1 159/4885CYP1A2 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.